Biogen’s litifilimab gained traction with new Phase 2 lupus readouts, with the company reporting improvements in another trial and building toward potential pivotal data. The latest results add to momentum around the anti-BDCA2 program as Biogen positions litifilimab to become a pillar of its immunology pipeline, targeting the inflammatory skin manifestations of lupus.